Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Mar 26;5(6):1666–1682. doi: 10.18632/oncotarget.1850

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2014 Correa et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

(A) Real-Time PCR analysis of NWD1 mRNA levels in a subset of prostate cell lines. RNA levels were normalized by cyclophilin (CPH) expression. Relative values (y-axis) were obtained after comparison to expression in normal prostate 267b1 cell line (mean value = 1). The values presented are averages of at least three replicates (+ standard deviation). (B) Stage-related expression of NWD1 in prostate cancer. A limited sampling of four disease stages, benign prostate hyperplasia (BPH) and normal tissues was evaluated by Real-Time PCR analysis. A representative graph illustrating the relative NWD1 expression using a pre-normalized cDNA panel, derived from respective tissue samples (n=48) at different tumor stages (TissueScan Prostate Cancer Tissue qPCR Panel I, HPRT101, Origene), is shown. (C) Comparative expression of NWD1 in normal and hyperplasic (BPH) tissues and stage II tumors. Relative values derived from (B) were re-plotted for stage II tumor samples with assigned Gleason score and reported TNM (n=7). (D) NWD1 protein distribution in human prostate specimens. A box and whisker plot depicts NWD1 immunoscore data for normal prostatic epithelium (NE), glandular hyperplasia (GH), BPH, atrophy (A), prostatic intraepithelial neoplasia (PIN), and prostate adenocarcinoma Gleason grade 2-5 (G2–G5). (E-K) TMA sections containing prostate specimens from 109 prostate cancer patients were immunostained for NWD1 using polymer-based EnVision-HRP-enzyme conjugate and DAB chromogen (brown). Representative examples of NWD1 protein expression in the normal prostatic epithelium (E), BPH (F), atrophy (G), PIN (H), and progressing prostate adenocarcinoma (I-K) are provided. Specimens were counterstained with hematoxylin. Bar ~ 100 μm. (L) Immunohistochemical detection of NWD1 protein in castration-resistant prostate cancers. A box and whisker plot depicts NWD1 immunoscore data for normal prostatic epithelium (NE), atrophy (A), basal cell hyperplasia (BCH), and prostate cancer with partial (Tpr) or no response (Tnr) to androgen deprivation therapy. (M-N) Serial TMA sections containing 66 cores of prostate specimens from 18 prostate cancer patients with partial or no response to androgen deprivation therapy were immunostained for NWD1 (M) and AR (N) using polymer-based EnVision-HRP-enzyme conjugate and DAB chromogen (brown). Specimens were counterstained with hematoxylin (M) and nuclear fast red (N). Bar ~ 100 μm.